Multiple Myeloma Awareness Month: When the Doctor Becomes the Caregiver

Read More

Browse our 650+ Publications​

Latest Publications

Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma

Beird H et al.
HGG Advances
February 2024
Authors and Affiliates
Hannah C. Beird; Chia-Chin Wu; Michael Nakazawa; Davis Ingram; Joseph R. Daniele; Rossana Lazcano; Latasha Little; Christopher Davies; Najat C. Daw; Khalida Wani; Wei-Lien Wang; Xingzhi Song; Curtis Gumbs; Jianhua Zhang; Brian Rubin; Anthony Conley; Adrienne M. Flanagan; Alexander J. Lazar and P. Andrew Futreal.

Antigen-presenting B cells promote TCF-1+ PD1-stem-like CD8+ T-cell proliferation in glioblastoma

Hou D et al.
Frontiers in Immunology
February 2024
Authors and Affiliates
David Hou; Hanxiao Wan; Joshua L. Katz; Si Wang; Brandyn A. Castro; Gustavo I. Vazquez-Cervantes; Victor A. Arrieta; Silpol Dhiantravan; Hinda Najem; Aida Rashidi; Tzu-yi Chia; Tarlan Arjmandi; Jimena Collado; Leah Billingham; Aurora Lopez-Rosas; Yu Han; Adam M. Sonabend; Amy B. Heimberger; Peng Zhang; Jason Miska and Catalina Lee-Chang.

Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation

Huuhtanen, J et al.
Nature
February 2024
Authors and Affiliates
Jani Huuhtanen; Shady Adnan-Awad; Jason Theodoropoulos; Sofia Forstén; Rebecca Warfvinge; Olli Dufva; Jonas Bouhlal; Parashar Dhapola; Hanna Duàn; Essi Laajala; Tiina Kasanen; Jay Klievink; Mette Ilander; Taina Jaatinen; Ulla Olsson-Strömberg; Henrik Hjorth-Hansen; Andreas Burchert; Göran Karlsson; Anna Kreutzman; Harri Lähdesmäki and Satu Mustjoki.

Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

Jabbour E, et al.
American Journal of Hematology
February 2024
Authors and Affiliates
Elias Jabbour1 | Gerhard Zugmaier2 | Vaibhav Agrawal3 | Pilar Martínez-Sánchez4 | José J. Rifon Roca5 | Ryan D. Cassaday6,7 | Boris Böll8 | Anita Rijneveld9 | Maher Abdul-Hay10 | Françoise Huguet11 | Thomas Cluzeau12 | Mar Tormo Díaz13 | Vladan Vucinic14 | José González-Campos15 | Alessandro Rambaldi16 | Stefan Schwartz17 | Céline Berthon18 | Jesús María Hernández-Rivas19,20,21 | Paul R. Gordon22 | Monika Brüggemann23 | Ali Hamidi22 | Yuqi Chen22 | Hansen L. Wong24 | Bharat Panwar22 | Yuliya Katlinskaya22 | Ana Markovic22 | Hagop Kantarjian1 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 2Amgen Research (Munich), GmbH, Munich, Germany 3Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California, USA 4Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), CNIO, CIBERONC, Madrid, Spain 5Hematology and Hemotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain 6Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA 7Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA 8First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Cologne, Germany 9Department of Hematology, Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands 10Perlmutter Cancer Center, New York University Langone Health, New York, New York, USA 11Department of Hematology, Institut Universitaire du Cancer-Oncopole CHU de Toulouse, Toulouse, France 12Université Nice Côte d'Azur, CHU de Nice, Nice, France 13Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigacion Sanitaria INCLIVA, Valencia, Spain 14Department of Hematology and Cell Therapy, University Hospital Leipzig, Leipzig, Germany 15Hematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain 16Department of Oncology-Hematology, University of Milan, Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy 17Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt- Universität zu Berlin, Campus Benjamin Franklin, Berlin, Germany 18Centre Hospitalier Universitaire de Lille, Lille, France 19IBSAL, IBMCC, CSIC, Cancer Research Center, University of Salamanca, Salamanca, Spain 20Department of Hematology, University Hospital of Salamanca, Salamanca, Spain 21CIBERONC, Research Group CB16/12/00233, Salamanca, Spain 22Amgen Inc., Thousand Oaks, California, USA 23Department of Hematology, University of Schleswig-Holstein, Kiel, Germany 24Clinical Pharmacology, Modeling and Simulation, Amgen Inc., South San Francisco, California, USA

Isatuximab in combination with carfilzomib anddexamethasone in 1q21þ patients with relapsed/refractorymultiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study

Facon T, et al.
hematological oncology
February 2024
Authors and Affiliates
Thierry Facon1 | Philippe Moreau2 | Ivan Špicka3 | Kenshi Suzuki4 | Kwee Yong5 | Joseph Mikhael6 | Taro Fukao7 | Kamlesh Bisht7 | Nicole M. Armstrong8 | Sandrine Macé9 | Marie‐Laure Risse10 | Thomas Martin11 1Department of Hematology, Lille University Hospital, Lille, France 2Department of Hematology, University Hospital Hôtel‐Dieu, Nantes, France 3Department of Hematology, 1st Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic 4Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan 5Department of Haematology, University College Hospital, London, UK 6Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, USA 7Sanofi, Global Oncology, Cambridge, Massachusetts, USA 8Sanofi, Global Medical Affairs, Cambridge, Massachusetts, USA 9Sanofi, Research and Development, Chilly‐ Mazarin, France 10Sanofi, Research and Development, Vitry‐ Sur‐Seine, France 11University of California San Francisco Medical Center, San Francisco, California, USA

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Stilgenbauer S, et al.
Blood Advances
January 2024
Authors and Affiliates
Stephan Stilgenbauer,1 Eugen Tausch,1 Andrew W. Roberts,2 Matthew S. Davids,3 Barbara Eichhorst,4 Michael Hallek,4 Peter Hillmen,5 Christof Schneider,1 Johannes Schetelig,6 Sebastian Böttcher,7 Arnon P. Kater,8 Yanwen Jiang,9 Michelle Boyer,9 Relja Popovic,10 Majd T. Ghanim,10 Michael Moran,10 Wendy J. Sinai,10 Xifeng Wang,10 Nabanita Mukherjee,10 Brenda Chyla,10 William G. Wierda,11,* John F. Seymour2,* 1Division of CLL, Internal Medicine III, Ulm University, Ulm, Germany; 2Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 4Department of Internal Medicine, Center of Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany; 5Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom; 6University Hospital, Technische Universität Dresden, Dresden, Germany; 7Division of Internal Medicine, Medical Clinic III-Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany; 8Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands; 9Genentech, South San Francisco, CA; 10AbbVie Inc, North Chicago, IL; 11The University of Texas MD Anderson Cancer Center, Houston, TX *Contributed equally.

SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMTCTN 2101)

Hill JA, et al.
January 2024
Authors and Affiliates
Joshua A. Hill, MD; Michael J. Martens, PhD; Jo-Anne H. Young, MD; Kavita Bhavsar, MSc; Jianqun Kou, MS; Min Chen, MS; Lik Wee Lee, PhD; Aliyah Baluch, MD; Madhav V. Dhodapkar, MBBS; Ryotaro Nakamura, MD; Kristin Peyton, BS; Dianna S. Howard, MD; Uroosa Ibrahim, MD; Zainab Shahid, MD; Paul Armistead, MD; Peter Westervelt, MD; John McCarty, MD; Joseph McGuirk, DO; Mehdi Hamadani, MD; Susan DeWolf, MD; Kinga Hosszu, PhD; Elad Sharon, MD, MPH; Ashley Spahn, BS; Amir A. Toor, MD; Stephanie Waldvogel, BS; Lee M. Greenberger, PhD; Jeffery J. Auletta, MD; Mary M. Horowitz, MD*; Marcie L. Riches, MD; Miguel-Angel Perales, MD

Daratumumab in Myeloma Patients With Early or Late Relapse After Initial Therapy: Subgroup Analysis of CASTOR and POLLUX.

Spencer A, et al.
Blood Advances
January 2024
Authors and Affiliates
Andrew Spencer, Philippe Moreau, M V Mateos, Hartmut Goldschmidt, Kenshi Suzuki, Mark-David Levin, Pieter Sonneveld, Robert Z Orlowski, Sung-Soo Yoon, Saad Z Usmani, Katja C Weisel, Donna Reece, Tahamtan Ahmadi, Huiling Pei, Wendy Garvin Mayo, Xue Gai, Jodi Carey, J Blake Bartlett, Robin Carson, Meletios-Athanasios A Dimopoulos
Previous Next